
Established in 2017 with offices in the UK and Taiwan, Biostone utilize a proprietary technology to create a new line of synthetic bone graft products to improve the clinical outcome and the life quality for the patient. Biostone received the US FDA 510K clearance for the first bone graft product, si-Mochi, in April 2021. In January 2023 Biostone also received the MDSAP certification with the standards and regulatory requirements of five different medical device markets including: Australia, Brazil, Canada, Japan, and the United States. Si-Mochi was created after years of academic and…
Annual RevenueBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Estimated OwnershipPrivateMatching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.